WallStSmart

Arxis, Inc. Class A Common Stock (ARXS)vsRTX Corporation (RTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

RTX Corporation generates 5182% more annual revenue ($93.50B vs $1.77B). RTX leads profitability with a 8.3% profit margin vs 7.2%. RTX trades at a lower P/E of 34.9x. RTX earns a higher WallStSmart Score of 59/100 (C).

ARXS

Avoid

35

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 4.0Quality: 7.5
Piotroski: 6/9Altman Z: 1.34

RTX

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.58

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARXS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.0%8/10

Revenue surging 25.0% year-over-year

RTX3 strengths · Avg: 8.7/10
Market CapQuality
$266.42B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
28.7%8/10

Earnings expanding 28.7% YoY

Free Cash FlowQuality
$3.59B8/10

Generating 3.6B in free cash flow

Areas to Watch

ARXS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.3%3/10

ROE of 0.3% — below average capital efficiency

Profit MarginProfitability
7.2%3/10

7.2% margin — thin

P/E RatioValuation
749.0x2/10

Premium valuation, high expectations priced in

RTX3 concerns · Avg: 4.0/10
PEG RatioValuation
2.304/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ARXS

The strongest argument for ARXS centers on Revenue Growth. Revenue growth of 25.0% demonstrates continued momentum.

Bull Case : RTX

The strongest argument for RTX centers on Market Cap, EPS Growth, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.

Bear Case : ARXS

The primary concerns for ARXS are EPS Growth, Return on Equity, Profit Margin. A P/E of 749.0x leaves little room for execution misses.

Bear Case : RTX

The primary concerns for RTX are PEG Ratio, P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

ARXS profiles as a growth stock while RTX is a value play — different risk/reward profiles.

ARXS is growing revenue faster at 25.0% — sustainability is the question.

RTX generates stronger free cash flow (3.6B), providing more financial flexibility.

Monitor AEROSPACE & DEFENSE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RTX scores higher overall (59/100 vs 35/100) and 14.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arxis, Inc. Class A Common Stock

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.

RTX Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization. Raytheon Technologies (RTX) researches, develops, and manufactures advanced technology products in the aerospace and defense industry, including aircraft engines, avionics, aerostructures, cybersecurity, guided missiles, air defense systems, satellites, and drones.

Visit Website →

Want to dig deeper into these stocks?